Track topics on Twitter Track topics that are important to you
Takeda TiGenix Announce Publication Lancet Week Results Phase PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Takeda TiGenix Announce Publication Lancet Week Results Phase articles that have been published worldwide.
We have published hundreds of Takeda TiGenix Announce Publication Lancet Week Results Phase news stories on BioPortfolio along with dozens of Takeda TiGenix Announce Publication Lancet Week Results Phase Clinical Trials and PubMed Articles about Takeda TiGenix Announce Publication Lancet Week Results Phase for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Takeda TiGenix Announce Publication Lancet Week Results Phase Companies in our database. You can also find out about relevant Takeda TiGenix Announce Publication Lancet Week Results Phase Drugs and Medications on this site too.
To evaluate whether scheduling a 2- to 3-week versus 6-week postpartum visit results in higher visit attendance.
Risankizumab, an anti-interleukin 23 antibody, was superior to placebo in achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction study in patients with moderately to severely active Crohn's disease. Here we aimed to assess the efficacy and safety of extended intravenous induction and subcutaneous maintenance therapy with risankizumab.
We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial comparing disease-free survival in patients with breast cancer with one or more micrometastatic (≤2 mm) sentinel nodes randomly assigned to either axillary dissection or no axillary dissection. The results showed no difference in disease-free survival between the groups and showed non-inferiority of no axillary dissection relative to axillary dissection. The current analysis presents the results of the study after a median follow-u...
A strategy of immobilizing lead in the framework of ferrite-ceramic matrix, to reduce its environmental hazard was explored in this study. The mechanisms of incorporating lead into lead ferrites (δ-phase (2PbO·FeO), γ-phase (PbO·(2-2.5)FeO) and β-phase (PbO·(5-6)FeO)) was revealed by observing the phase transformation in the products. The δ-phase was dominantly formed at low temperature of 700-800 °C at Pb/Fe of 1/1-1/3. The significant growth of γ-phase was observed at 750-850 °C and Pb/Fe of...
Methylphenidate (MP) is a commonly prescribed psychostimulant for Attention Deficit Hyperactivity Disorder (ADHD). We recently reported behavioral and developmental effects of chronic MP use in healthy rats. The current study investigated how interrupting chronic MP treatment with weekend abstinence altered the behavioral and physiological consequences of chronic MP treatment, and if prolonged abstinence would reverse the observed effects. Male Sprague Dawley rats were assigned to one of three treatment gro...
Comfort, P, Dos'Santos, T, Thomas, C, McMahon, JJ, and Suchomel, TJ. An investigation into the effects of excluding the catch phase of the power clean on force-time characteristics during isometric and dynamic tasks: an intervention study. J Strength Cond Res XX(X): 000-000, 2018-The aims of this study were to compare the effects of the exclusion or inclusion of the catch phase during power clean (PC) derivatives on force-time characteristics during isometric and dynamic tasks, after two 4-week mesocycles o...
We report results from a prospective phase I/II trial for patients with centrally-located, early-stage non-small cell lung cancer (NSCLC) receiving stereotactic body radiation therapy (SBRT).
Nunes, RFH, Cidral-Filho, FJ, Flores, LJF, Nakamura, FY, Rodriguez, HFM, Bobinski, F, De Sousa, A, Petronilho, F, Danielski, LG, Martins, MM, Martins, DF, and Guglielmo, LGA. Effects of far-infrared emitting ceramic materials on recovery during 2-week preseason of elite futsal players. J Strength Cond Res XX(X): 000-000, 2018-We investigated the effects of far-infrared emitting ceramic materials (cFIR) during overnight sleep on neuromuscular, biochemical and perceptual markers in futsal players. Twenty athl...
Norovirus is the leading cause of acute gastroenteritis (AGE) worldwide. In the United States norovirus is estimated to cause 19-21 million illnesses, 1.7-1.9 million outpatient visits, 56,000-71,000 hospitalizations, and 570-800 deaths annually. Through direct costs and loss of productivity, norovirus disease cost the US economy more than $5.5 billion annually. Due to the lack of available therapies to treat norovirus infections and their highly infectious nature, preventing norovirus illness through va...
Secukinumab is a recombinant monoclonal antibody that prevents interleukin 17A (IL-17A) from binding to its receptor, thus limiting inflammatory processes ultimately leading to excessive keratinocyte proliferation. According to phase-III clinical trials, it significantly reduces disease severity within a short period of time (PASI75>80% at week 12). Three real-life studies (47, 69 & 83 patients each) showed that 72.30%, 52.90% & 80.00% of treated subjects respectively achieved PASI75 at week 12. Still, more...
The results of the randomized phase 3 CREST trial evaluating the use of thoracic radiotherapy for extensive-stage small-cell lung cancer (ES-SCLC) were published in the Lancet in 2015. The primary endpoint (10% overall survival difference at 1-year) was not achieved, but there was significant improvement in 2-year overall survival (13% vs 3%; p = 0.004) and low toxicity rates, suggesting thoracic radiotherapy should be considered for ES-SCLC patients who respond to chemotherapy. Questions have been rais...
This randomized, double-blind (DB), placebo-controlled, phase 2 study assessed the efficacy and safety of fulranumab as a pain therapy adjunctive to opioids in terminally-ill cancer patients. Ninety-eight patients were randomized (2:1) to receive one subcutaneous injection of fulranumab (9 mg) or placebo in the 4-week DB phase. Seventy-one (72%) patients entered the 48-week open-label extension phase and were administered 9 mg fulranumab every 4 weeks. The study failed to demonstrated efficacy at the end of...
Brain-computer interface (BCI) technology is attracting increasing interest as a tool for enhancing recovery of motor function after stroke, yet the optimal way to apply this technology is unknown. Here, we studied the immediate and therapeutic effects of BCI-based training to control pre-movement sensorimotor rhythm (SMR) amplitude on robot-assisted finger extension in people with stroke. Approach. Eight people with moderate to severe hand impairment due to chronic stroke completed a 4-week 3-phase pr...
Previous randomised studies showed that withholding parenteral nutrition for 1 week of critical illness was superior to early initiation (